Fabtech Technologies Starts Trading at a Price of ₹192 on NSE, Equivalent to the Issue Price.

Mumbai, October 7, 2025: Fabtech Technologies Limited shares saw a steady start on Tuesday, with shares trading at ₹192 on the NSE. The trading price was quite close to its issue price of ₹191. The ₹230 crore initial public offering (IPO) had a muted start due to the whole market being volatile.

Fabtech Technologies IPO is a Mumbai-based firm that offers comprehensive engineering solutions for healthcare, biotech, and the pharmaceutical industry. It offers a variety of services, from bio-clean air systems to clean water systems to process engineering. The company completed a total of 51 projects spread across Asia, Africa, and the Middle East, and it also caters to customers spread across more than 62 nations. Fabtech wishes to deploy funds realised via IPO to expand its business across the globe and make it easy for it to complete projects.

Fabtech Technologies Performance of the Listing

Following the listing, shares of Fabtech slipped to an intraday low of ₹182.40, before stabilising around the same level by 12:16 pm IST, marking a 5.00% decline from the listing price. The stock had opened at ₹192 and touched an intraday high of ₹192.50 in the early hours of trade. Analysts attributed the muted performance to a cautious market sentiment, short-term traders offloading positions, and the mandatory 100% upfront settlement requirement. During the session, 13.36 lakh shares changed hands, giving the company a market capitalisation of ₹813.45 crore.

Fabtech Technologies Investor Reaction and Subscription

Despite the subdued listing, the IPO garnered strong investor interest. Retail investors subscribed 2.08 times their allotted shares, while Qualified Institutional Buyers (QIBs) subscribed 2.02 times their allocation. The robust subscription reflects confidence in the company’s asset-light business model and its potential to expand through a global footprint.

Although the listing opened flat, industry experts believe Fabtech’s robust global projects portfolio and expertise in turnkey solutions position it for long-term growth. Its specialization in designing products that meet stringent quality and regulatory requirements provides a strategic advantage, particularly as the biotech and pharmaceutical sectors continue to expand rapidly.

REF: https://www.nseindia.com/get-quotes/equity?symbol=FABTECH

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations